Africa should not wait for a synthetic drug crisis before strengthening harm reduction systems

By Pharmacist Melody Okereke

Public health systems are often most responsive after a crisis becomes visible. In harm reduction, that delay can be costly. Africa does not need to wait for a widespread synthetic opioid crisis before strengthening its harm reduction systems.

The warning signals are already present. The question is whether systems are prepared to act on them early enough.

Global experience offers a clear lesson. Where synthetic opioids such as fentanyl and nitazenes have entered drug markets, health systems that lacked established harm reduction infrastructure struggled to respond in time.

Overdose surveillance was weak. Naloxone availability was limited. Community-based early warning systems were underdeveloped. The result was not just increased mortality, but rapid system overload.

The assumption that Africa is “not yet affected” is increasingly difficult to defend. While large-scale synthetic opioid outbreaks have not been documented across many African settings in the same way as North America, multiple indicators suggest growing vulnerability.

These include increased circulation of mixed substance use patterns, limited toxicology capacity, weak drug market surveillance systems, and rising poly-substance use among younger populations in urban settings.

In several Nigerian cities, for example, harm reduction and HIV programme implementers have reported increasing complexity in substance use profiles among clients. Stimulant use, prescription opioid misuse, and unregulated pharmaceutical diversion are becoming more common in service delivery settings originally designed for more traditional patterns of drug use.

These are not yet synthetic opioid epidemics, but they are system stress signals.

The issue is not only the substances themselves. It is the absence of preparedness infrastructure.

In many African health systems, harm reduction remains narrowly integrated into HIV programming or implemented through donor-funded projects with limited scale. Core components of a synthetic drug response system, such as overdose surveillance, community-based early warning mechanisms, naloxone distribution systems, and real-time drug checking capacity, are either absent or extremely limited.

This creates a structural gap between risk evolution and system readiness.
From a health systems perspective, this is a predictable vulnerability.

Drug markets are increasingly globalised and adaptive. Synthetic substances are easier to manufacture, more difficult to detect, and more potent

In settings without established harm reduction infrastructure, even small shifts in drug supply can produce disproportionate health impacts.

Real-world experience from other regions illustrates this clearly. In North America, the rapid escalation of fentanyl-related overdose deaths was not solely a function of drug availability. It was also a function of delayed system adaptation.

Harm reduction tools such as widespread naloxone access, supervised consumption sites, and drug checking services were not scaled at the same pace as the evolving risk environment.

The lesson is not that Africa is experiencing the same epidemic. The lesson is that waiting for full-scale emergence before building response systems is a high-risk strategy.

There are also operational realities within African health systems that increase vulnerability. Toxicology capacity is limited in many settings. Routine drug market surveillance is weak or fragmented. Emergency response systems are often not linked to community-based harm reduction actors.

These constraints reduce the ability to detect and respond early to changes in substance composition or overdose patterns.

At the same time, community-based organisations are often the first to observe shifts in drug use trends. Peer networks, outreach programmes, and HIV service delivery points frequently detect changes in client behaviour long before they appear in formal datasets.

However, these signals are rarely integrated into national early warning systems. This is where the gap becomes critical.

Harm reduction preparedness is about system integration. Early warning mechanisms, community-led monitoring, and rapid response protocols need to be embedded within existing HIV and primary health care systems.

Without this, detection will remain informal and response will remain delayed.

There is also a financing dimension. Most harm reduction funding in Africa remains tied to HIV programming cycles and donor priorities.

Synthetic drug preparedness requires investment in systems that may not show immediate programme outputs, such as surveillance infrastructure, workforce training, and emergency response coordination.

These are often underfunded because they are perceived as future-oriented rather than immediate priorities. This is a strategic miscalculation.

Preparedness systems are most effective when built before pressure peaks. Once a synthetic drug crisis fully emerges, the cost of delayed response increases exponentially, both in human lives and system disruption.

The policy argument is therefore not speculative. It is preventive. Strengthening harm reduction systems now is not about responding to a crisis that has already arrived. It is about building resilience for a risk environment that is already evolving.

Africa does not need to replicate the exact trajectory of other regions to justify action. It only needs to recognise that drug markets are increasingly interconnected, and that system readiness is a determinant of outcome severity.

The future effectiveness of harm reduction in Africa will depend on whether health systems continue to treat synthetic drug risk as a distant concern or begin integrating preparedness into current programming.

The evidence from other regions is clear. Waiting for full scale crisis to emerge is not a neutral position. It is a delayed response strategy with predictable consequences.

Melody Okereke is a clinical pharmacist and implementation science researcher working on harm reduction, HIV/AIDS programming, and health systems innovation with a focus on community-led and implementation-driven models.